3. Fillbrunn M, Signorovitch J, André F, et al. PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: a meta-analysis of published clinical trials. BMC Cancer. 2022;22(1):1002. 4
[6]Hassan F, Wang JH, O'Leary DP, et al Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer. Surg O...
[2]Bonotto, M., Gerratana, L., Poletto, E., et al. (2014). Measures of outcome in metastatic breast cancer: insights from a real-world scenario. The oncologist, 19(6), 608–615.[3]Criscitiello C, Marra A, Curigliano G. PIK3CA Mutation Assessment in HR+/HER2− Metastatic Breas...
Activating mutations in phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) gene frequently occur in breast cancer, and are important for the survival of patients with breast cancer. Although PIK3CA mutations have been studied widely in many countries, the relationships between PIK3CA ...
PIK3CAmutation occurs frequently in HER2-positive disease (20%–25% of patients), yet the evidence surrounding its significance on cancer or treatment outcomes remains unclear. This meta-analysis suggestsPIK3CAmutation does, in fact, affect patient outcomes. ...
Several combination therapies based on PI3K inhibition have been proposed, but a way to systematically prioritize them for breast cancer treatment is still missing. By integrating published and in-house studies, we have developed in silico models that quantitatively capture dynamics of PI3K signaling ...
Patients were excluded if they had metaplastic breast cancer; had a history of leptomeningeal disease or carcinomatous meningitis; received any prior systemic therapy for metastatic breast cancer; had prior treatment with fulvestrant or any selective estrogen receptor degra...
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2. Br J Cancer. 2017;116:726-30.Moynahan ME; Chen D; He W;.Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2...
Guidelines on tests of PIK3CA mutation in breast cancer in China (2025 version) Chinese Society of Pathology Pathology Expert Committee of Chinese Society of Clinical Oncology Pathology Quality Control Center Liang Zhiyong Wu Jiong Bu Hong Authors Info & Affiliations Published: 2025 -02 -...
6.https://novartis.gcs-web.com/FDA-approves-Novartis-Piqray-the-first-and-only-treatment-specifically-for-patients-with-a-PIK3CA-mutation-in-HRHER2-advanced-breast-cancer 本站仅提供存储服务,所有内容均由用户发布,如发现有害或侵权内容,请